A matter of effective portfolio management, funding and strategic partnerships?
flanders.bio and CMAST warmly invite you to the first edition of their Partner Day, focusing on how to overcome key challenges when realizing innovation with impact.
Testimonials by representatives from both industry and academia will give insight into the value of portfolio management, funding and strategic partnerships in innovation projects:
A vivid panel discussion with academic, SME, pharma and patient group representatives will address “The critical success factors and pitfalls in multi-stakeholder innovation platforms”.
Interactive workshops build further on the topics of the day, aiming to uncover concrete solutions.
Please join us as an engaged partner eager to realize impact through your innovation projects!
Board Member at several biotech companies
Professor, University of Antwerp & UZA
Sr. Director Health Information Sciences, Janssen
CEO, Confo Therapeutics
Partner & Chief Innovation, CMAST
Managing Director, Immuno Valley
Chief Medical Officer, Cubigo
EU-Research Project Officer, GAMIAN / Ups en Downs
Global Business Leader, Janssen Diagnostics
flanders.bio & CMAST
Hilde Windels, member of the Board of Directors of Ablynx, MyCartis, BioCartis NV, VIB and Erytech Pharma
Herman Goossens, Professor of Medical Microbiology at the University of Antwerp and Director of the Dept. of Clinical Pathology of the University Hospital Antwerp
Bart Vannieuwenhuyse, Senior Director Health Information Sciences, Janssen
Cedric Ververken, CEO, Confo Therapeutics
Featuring: Bart Vannieuwenhuyse (Janssen), Peter Willems (Cubigo), Liana Steeghs (Immuno Valley), Erik Van der Eycken (GAMIAN / Ups en Downs) and Kurt Hertogs (CMAST)
Moderated by: Jan Schrooten (RegMed)
Daap Kooij, Global Business Leader, Janssen Diagnostics
Elisabeth Center Antwerp, Koningin Astridplein 26, 2018 Antwerp
40 €* for flanders.bio members
80 €* for non-members
* VAT excluded
FLANDERS.BIO MEMBER BENEFIT: flanders.bio members receive a 50% reduction on the registration fee.